BRISBANE, Calif. — November 10, 2025 — Leads & Copy — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, announced that the company’s management team will present at the TD Cowen Immunology & Inflammation Summit, taking place virtually from November 12-13, 2025.
The management team will also participate in one-on-one investor meetings.
The presentation details are as follows:
Date: Thursday, November 13, 2025
Time: 1:30pm ET
Webcast: https://wsw.com/webcast/cowen185/vera/2021228
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of Vera Therapeutics’ website.
Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. The company’s lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis.
Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. Vera Therapeutics holds an exclusive license agreement with Stanford University for VT-109, a novel, next generation fusion protein targeting BAFF and APRIL, with wide therapeutic potential across the spectrum of B-cell–mediated diseases.
Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868.
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
Source: Vera Therapeutics
